Emerging drugs for the treatment of pancreatic cancer

Expert Opinion on Emerging Drugs

Volumn 12, Issue 2, 2007, Pages 301-311

  Van Laethem, Jean Luc ^a   Marechal, Raphael ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Anti EGF receptor therapy; Antiangiogenic therapy; Chemotherapy; Desmoplastic reaction; Growth factors; Pancreatic cancer; Receptor tyrosine kinase inhibitors; Targeted therapy; Translational research; Xenograft model

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CISPLATIN; CURCUMIN; ERLOTINIB; EVEROLIMUS; EXATECAN; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MATRIX METALLOPROTEINASE; MATUZUMAB; OXALIPLATIN; PANITUMUMAB; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALATINIB;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PANCREAS CANCER; PHENOTYPE; QUALITY OF LIFE; REVIEW; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 34250699015     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.2.301     Document Type: Review

References (66)

1. LI D, XIE K, WOLFF R et al.: Pancreatic cancer. Lancet (2004) 363:1049-1057.
2. PARKIN DM, BRAY FI, DEVESA SS et al.: Cancer burden in the year 2000. The global picture. Eur. J. Cancer (2001) 37:S4-S66.
3. BURRIS H, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J. Clin. Oncol. (1997) 15:2403-2413.
4. HEINEMANN V: Gemcitabine: progress in the treatment of pancreatic cancer. Oncology (2001) 60:8-18.
5. GLIMELIUS B, HOFFMAN K, SJODEN PO et al.: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. (1996) 7:593-600.
6. LOUVET C, LABIANCA R, HAMMEL P et al.: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer; results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. (2005) 23:3509-3516.
7. ABOU-ALFA GK, LETOURNEAU R, HARKER G et al.: Randomized Phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J. Clin. Oncol. (2006) 24:4441-4447.
8. ROCHA-LIMA CM, SAVARESE D, BRUCHNER H et al.: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. (2004) 18:3776-3783.
9. OETTLE H, RICHARDS DL, RAMANATHAN RK et al.: A Phase III trial of permetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol. (2005) 16:1639-1645.
10. HEINEMANN V, QUIETZSCH D, GIESELER F et al.: Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. (2006) 24:3946-3952.
11. BERLIN JD, CATALANO P, THOMAS JP et al.: Phase III srudy of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. (2002) 20(15):3270-3275.
12. HERRMANN R, BODOKY G, RUHSTALLER B et al.: Gemcitabine plus capecitabine versus gemcitabine alone in locally advanced or metastatic pancreatic cancer: a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). Proc. ASCO J. Clin. Oncol. (2005) 2:Abstract 4010.
13. CUNNINGHAM D, CHAN I, STOCKEN D et al.: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur. J. Cancer (2005) (Suppl. 3):Abstract PS11.
14. POPLIN E, LEVY DE, BERLIN J et al.: Phase III trial of gemcitabine (30 minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatine (GEMOX) in patients with APC (E 6201). Proc. ASCO J. Clin. Oncol. (2006) 24(Suppl. 1):185 (Abstract 4004).
15. TEMPERO M, PLUNKETT W, RUIZ VAN HAPERIN V et al.: Randomized Phase II comparison of dose-intense gemcitabine; thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol. (2003) 21:3402-3408.
16. OETTLE H, POST P, NEUHAUS P et al.: Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA (2007) 297:267-277.
17. CRANE CH, WOLFF RA, ABRUZZEZE JL et al.: Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin. Oncol. (2001) 28:25-33.
18. MORIZANE C, OKUSAKA T, FURUSE J et al.: A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Proc. ASCO J. Clin. Oncol. (2006) 24(Part I):185 Abstract 4115.
19. YAMANAKA Y, FRIESS H, KOBRIN MS et al.: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. (1993) 13:565-569.
20. OVERHOLSER JP, PREWETT MC, HOOPER AT et al.: Epidermal growth factor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer (2000) 89:74-82.
21. HUANG ZQ, BUCHSMAUM DJ, RAISCH KP et al.: Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J. Surg. Res. (2003) 111:274-283.
22. XIONG HQ, ROSENBERG A, LOBUGLIO A et al.: Cetuximab, a monocloncal antibody targeting the epidermal growrh factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II trial. J. Clin. Oncol. (2004) 22:2610-2616.
23. GRUNWALD V, HIDALGO M: Development of the epidermal growth factor receptor inhibitor OSI-774. Semin. Oncol. (2003) 30:23-31.
24. ROSETTI M, TESEI A, ULIVI P et al.: Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines. Cancer Biol. Ther. (2005) 4:1089-1095.
25. MOORE MJ, GOLDSTEIN D, HAMM J et al.: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trial Group [NCIC-CTG]. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 1a.
26. SEQUIST LV, BELL DW, LYNCH TJ et al.: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. (2007) 25:587-595.
27. KWAK EL, JANKOWSKI J, THAYER SP et al.: Epidermal growrh factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res. (2006) 12:4283-4287.
28. YAMANAKA Y, FRIESS H, KOBRIN MS et al.: Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum. Pathol. (1993) 24:1127-1134.
29. SAFRAN H, IANNITTI D, RAMANATHAN R et al.: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. (2004) 22:706-712.
30. JOHNSTON SR, LEARY A: Lapatinib: a novel EGFR/Her2 tyrosine kinase inhibitor for cancer. Drugs Today (2006) 42:441-453.
31. BAKER CH, SOLORZANO CC, FIDLER IJ: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. (2002) 62:1996-2003.
32. SEO Y, BABA H, FUKUDA T et al.: High expression of vascular endotelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer (2000) 88:2239-2245.
33. DE GRAMONT A, VAN CUTSEM E: Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology (2005) 69:46-56.
34. KINDLER HL, NIEDZWIECKI D, HOLLIS E et al.: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. ASCO GI (Orlando) (2007):Abstract 108.
35. CRANE CH, ELLIS LM, ABBRUZZESE JL et al.: Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J. Clin. Oncol. (2006) 24:1145-1151.
36. YOKOI K, SASAKI T, BUCANA CD et al.: Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res. (2005) 65:10371-10380.
37. MOLINA MA, SITJA-ARNAU M, LEMOINE MG et al.: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroid anti-inflammatory drugs. Cancer Res. (1999) 59:4356-4362.
38. EL-RAYES BF, ZALUPSKI MM, SHIELDS AF et al.: A Phase II study of celecoxib, gemcitabine and cisplatin in advanced pancreatic cancer. Invest. New Drugs (2005) 23:583-590.
39. XIANG HQ, HESS KR, KAYALEH OR et al.: A Phase II trial of gemcitabine and celecoxib for metastatic pancreatic cancer. Proc. ASCO J. Clin. Oncol. (2005) 23(Part I):165 Abstract 4174.
40. ZALATNAI A: Molecular aspects of stromal - parenchymal interactions in malignant neoplasms. Cur. Mol. Med. (2006) 6:685-693.
41. BRAMHALL SR, SCHULZ J, NEMUNAITIS J et al.: A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer (2002) 87:161-167.
42. JASNER R: Molecular regulation of pancreatic stellate cell function. Mol. Cancer (2004) 3:1-8.
43. SMORENBURG SM, VAN NOORDEN CJF: The complex effects of heparine on cancer progress and metastasis in experimental studies. Pharm. Rev. (2001) 1:93-106.
44. LUDWIGR J, ALBAN S, BISTRIAN R et al.: The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb. Haemost. (2006) 95(3):535-540.
45. KLERK CP, SMORENBURG SM, OTTEN HM et al.: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. (2005) 23:2130-2135.
46. PELZER U, HILBIG A, STIELER J et al.: A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin chemotherapy (PROSPECT-CONKO 004). Proc. ASCO J. Clin. Oncol. (2006) 24(Part I):185 Abstract 4110.
47. VAN CUTSEM E, VANDE VELDE H, KARASEH P et al.: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. (2004) 22:1430-1438.
48. LIEVRE A, BACHET JB, LE CORRE D et al.: KRAS mutations status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. (2006) 66:3992-3995.
49. VIVANCO I, SAWYERS CL: The phosphatidyl inositol 3 kinase AKT pathway in human cancer. Nat. Rev. Cancer (2002) 2:489-501.
50. DANCEY JE: Therapeutic targets: mTOR and related pathways. Cancer Biol. Ther. (2006) 5:1065-1073.
51. HOSSHINO R, CHATANI Y, YAMORI T et al.: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene (1999) 18:813-822.
52. LORUSSO PM, ADJEI AA, VARTERASIAN M et al.: Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. (2005) 23:5281-5293.
53. CHOI M, WANG S, BANERJEE S et al.: Bcl-2 and Bd-xL targeted therapy inhibits growth of pancreatic cancer cells. Gastrointestinal Cancers Symposium (2006): Abstract 143.
54. KARIN M: Nuclear factor-kappa B in cancer development and progression. Nature (2006) 441:431-436.
55. LI L, AGGARWAL BB, SHISHODIA S et al.: Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their downregulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer (2004) 101:2351-2362.
56. LI L, BRAITEH FS, KURZROCK RL: Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signalling, and angiogenesis. Cancer (2005) 104:1322-1331.
57. ALBERTS SR, FOSTER NR, MORTO RF et al.: PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann. Oncol. (2005) 16:1654-1661.
58. KEITH WN, BILSLAND A, EVANS TR et al.: Telomerase-directed molecular therapeutics. Expert Rev. Mol. Med. (2002) 20:1-25.
59. GORDON JN, TREBBLE TM, ELLIS RD et al.: Thalidomid in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut (2005) 54:540-545.
60. DEMETRI GD, VAN OOSTEROM AT, GARRETT CR et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 368(9544):1329-1338.
61. DEEKS ED, KEATING GM: Sunitinib. Drugs (2006) 66(17):2255- 2266.
62. ESCUDIER B, EISEN T, STADLER WM et al.: Sorafenib in advanced clear-cell rena-cell carcinoma. N. Engl. J. Med. (2007) 356(2):185-187.
63. WALLACE JA, LOCKER G, NATTAM S et al.: Sorafenib plus gemcitabine for advanced pancreatic cancer: a Phase II trial of the University of Chicago Phase II consortium. ASCO GI (Orlando) (2007):Abstract 137.
64. YOKOI K, THABER PH, YAZICI S et al.: Dual inihibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res. (2005) 65:3716-3725.
65. LI C, HEIDT DG, DALERBA P et al.: Identification of pancreatic cancer stem cells. Cancer Res. (2007) 67(3):1030-1037.
66. HIDALGO M, RUBIO-VIQUEIRA B, WEEKES C et al.: In vivo platform for translational drug development and biomarker discovery in pancreatic cancer. Proc. ASCO J. Clin. Oncol. (2006) 24(Part I)185 Abstract 4000.